anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: The purpose of the study is to construct meaningful nomogram models according to the independent prognostic factor for metastatic pancreatic cancer receiving chemotherapy.
METHODS: This study is retrospective and consecutively included 143 patients from January 2013 to June 2021. The receiver operating characteristic (ROC) curve with the area under the curve (AUC) is utilized to determine the optimal cut-off value. The Kaplan-Meier survival analysis, univariate and multivariable Cox regression analysis are exploited to identify the correlation of inflammatory biomarkers and clinicopathological features with survival. R software are run to construct nomograms based on independent risk factors to visualize survival. Nomogram model is examined using calibration curve and decision curve analysis (DCA).
RESULTS: The best cut-off values of 966.71, 0.257, and 2.54 for the systemic immunological inflammation index (SII), monocyte-to-lymphocyte ratio (MLR), and neutrophil-to-lymphocyte ratio (NLR) were obtained by ROC analysis. Cox proportional-hazards model revealed that baseline SII, history of drinking and metastasis sites were independent prognostic indices for survival. We established prognostic nomograms for primary endpoints of this study. The nomograms' predictive potential and clinical efficacy have been evaluated by calibration curves and DCA.
CONCLUSION: We constructed nomograms based on independent prognostic factors, these models have promising applications in clinical practice to assist clinicians in personalizing the management of patients.
BACKGROUND: The chronic digestive condition gallstones is quite common around the world, the development of which is closely related to oxidative stress, inflammatory response and abnormalities of lipid metabolism. In the last few years, as a novel biomarker of lipid metabolism, the non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) has garnered significant interest. However, its relationship with gallstones has not been studied yet.
METHODS: 3,772 people, all under 50, were included in this study, and their full data came from the National Health and Nutrition Examination Survey (NHANES) database for the years 2017-2020. Information on gallstones was obtained through self-reported questionnaires. Smoothed curve fitting multifactorial logistic regression was utilized to evaluate the connection of NHHR with gallstone formation incidence. Subsequently, subgroup analysis and interaction tests were applied. Finally, to create a prediction model, logistic regression and feature screening by last absolute shrinkage and selection operator (LASSO) were used. The resulting model was displayed using a nomogram.
RESULTS: In multivariate logistic regression that accounted for all factors, there was a 77% increase in the likelihood of gallstones for every unit rise in lnNHHR (OR 1.77 [CI 1.11-2.83]). Following NHHR stratification, the Q4 NHHR level was substantially more linked to the risk of gallstones than the Q1 level (OR 1.86 [CI 1.04-3.32]). This correlation was stronger in women, people under 35, smokers, abstainers from alcohol, non-Hispanic White people, those with excessively high cholesterol, people with COPD, and people without diabetes. After feature screening, a predictive model and visualized nomogram for gallstones were constructed with an AUC of 0.785 (CI 0.745-0.819), which was assessed by DCA to be clinically important.
CONCLUSION: In the group of people ≤ 50 years of age, elevated NHHR levels were substantially linked to a higher incidence of gallstones. This correlation was stronger in several specific groups such as females, under 35 years of age, smokers, and so on. Predictive models constructed using the NHHR have potential clinical value in assessing gallstone formation.
L-Methionine is a known essential and natural amino acid, which plays a critical role in cellular metabolic pathways and tissue functions in humans. Currently, there is not commercial or reported pharmaceutical form for use in human. To overcome difficulties in patients and particularly in pediatric use, the development of an oral and stable pharmaceutical presentation is needed. The inventors design an easy to prepare, stable pharmaceutical formulation of Methionine in the form of a powder ready to be orally used after mixing with a specific amount of aqueous solvent such as water. The methionine formulation was also optimized for palatability and acceptability like smell, taste and texture, as methionine is also well known for its strong unpleasant smelling and taste. Accordingly, the present invention relates to a pharmaceutical composition comprising methionine or a methionine-compound donor or any one of their pharmaceutically acceptable salts and uses thereof as a drug.
INTRODUCTION: Jaundice is a common condition that requires integrating knowledge of biochemistry, physiology, pathology, and general medicine. However, medical students face difficulty in learning with passive teaching methods. To enhance their learning, an educational story game that promotes active learning and assessment with immediate feedback was implemented.
METHODS: This jaundice game was named Livogena: The Ikteros Curse-denoting the liver as the principal organ and jaundice (icterus) as a problem. One hundred fifty first-year medical students were divided into small groups to play using a game board and cards. The players moved ahead on the game board by providing the correct answer and completing the activities. The first team to reach the end was the winner. Perceptions and feedback questionnaires were distributed to students at the end of the game. Individual views about the game were recorded for qualitative analysis. Also, to analyze the effectiveness of this intervention, pre- and posttests on jaundice were conducted.
RESULTS: Livogena: The Ikteros Curse resulted in a highly significant improvement in students' knowledge and application skills in jaundice, from 5.5 (SD = 2.4) in the pretest to 11.2 (SD = 7.6) in the posttest for 20 marks (p < .001). Students perceived and rated the game exceptionally positively.
DISCUSSION: This educational game significantly increased learners' understanding of the concepts of jaundice. Highly positive perceptions from students further affirm this to be a creative innovation to enhance their learning and application of knowledge in an active and team-based learning environment.
In delayed oral feeding group the patients receive isotonic saline by the nasoenteral feeding tube at 20 mL/h until the morning of post operative day1. Nutrition was then commenced at 20 mL/h. The rate was increased by 20 mL/h each day if tolerated, up to 80 mL/h.Esophagography was performed on postoperative day 7. Sip of water were allowed after confirming the absence of anastomosis leakage, and a full liquid diet was implemented on the following day and enteral infusion halted.
The invention belongs to the field of research on LDLR genes, and particularly relates to a novel mutant gene related to hypercholesterolemia and an application thereof. A nucleic acid comprising a target fragment having a c.1879g > a mutation compared to a wild-type LDLR gene fragment. A polypeptide having a p.a627t mutation compared to wild type LDLR. The application of the gene segment in preparing the medicine for preventing and treating hypercholesterolemia is the gene segment with G as c.1879 site mononucleotide of LDLR. The medicine for preventing and treating hypercholesterolemia at least comprises one of a.C 1879G > A mutation inhibitor of LDLR gene, b.P.A627T mutation inhibitor of LDLR gene and c.gene segment, wherein the gene segment is the gene segment with G as c.1879 site mononucleotide of LDLR gene. The invention discovers a new mutation site c.1879G > A of the LDLR gene, and the detection of the mutation site can be used for the auxiliary diagnosis of hypercholesteremia patients; has important significance for diagnosing and treating hypercholesterolemia.
The safety and effectiveness of pantoprazole sodium for injection for the treatment of GERD and a history of EE for up to 7 days have been established in pediatric patients 3 months of age and older. Use of pantoprazole sodium for injection for this indication is supported by evidence from adequate and well-controlled studies of intravenous and oral pantoprazole sodium in adults and oral pantoprazole sodium in pediatric patients, with additional pharmacokinetic and safety data of intravenous pantoprazole in pediatric patients 1 year of age and older and oral pantoprazole in pediatric patients 3 months of age and older. Adverse reactions were generally similar to those reported in adults with intravenous or oral pantoprazole sodium [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3)].

The safety and effectiveness of pantoprazole sodium for injection have not been established in patients less than 3 months of age for the treatment of GERD and a history of EE.

The safety and effectiveness of pantoprazole sodium for injection have not been established in pediatric patients for the treatment of pathological hypersecretory conditions including ZE syndrome.

Animal Toxicity Data

In neonatal/juvenile animals (rats and dogs) toxicities were similar to those observed in adult animals, including gastric alterations, decreases in red cell mass, increases in lipids, enzyme induction and hepatocellular hypertrophy. An increased incidence of eosinophilic chief cells in adult and neonatal/juvenile rats, and atrophy of chief cells in adult rats and in neonatal/juvenile dogs, was observed in the fundic mucosa of stomachs in repeated-dose studies. Full to partial recovery of these effects were noted in animals of both age groups following a recovery period.
Subjects were randomly allocated to receive SCL or CCL. SCL consisted of full thickness flaps followed by bone recontouring and minor gingivectomy 4 months postoperatively, if required. In CCL, osseous recontouring after sub-marginal incisions was performed, followed by flap repositioning. Records were obtained at baseline, 4 months (only in SCL), 6 and 12 months. Primary outcome was the precision in achieving a predetermined gingival margin position. Other outcomes were changes in the gingival margin position and keratinized tissue width (KTW) at 12 months, and patient-reported outcomes (PROMs) using the OHIP-14 tool.
Metastatic cancer remains a formidable challenge in anticancer therapy. Despite efforts to develop effective antimetastasis drugs over the past half-century, currently approved treatments fall short of expectations. This report highlights the promising antiproliferative activity of a ruthenium-based therapeutic agent, namely dichlorido(p-cymene)[2-amino-4-(pyridin-3-yl)-4H-benzo[h]-chromene-3-carbonitrile]ruthenium(II) (complex 1) against metastatic cell lines. Complex 1 shows significant efficacy in metastatic LoVo and Du-145 cell lines at nanomolar concentrations, being markedly more active than clinically used anticancer cisplatin. Studies on the MDA-MB-231 cell line, which displays invasive characteristics, demonstrated that 1 significantly reduces cell invasion. This efficacy was confirmed by its impact on matrix metalloproteinase production in MDA-MB-231 cells. Given that cell migration drives cancer invasion and metastasis, complex 1's effect on MDA-MB-231 cell migration was evaluated via wound healing assay and vimentin network analysis. Results indicated a strong reduction in migration. A re-adhesion assay further demonstrated that 1 significantly lowers the re-adhesion ability of MDA-MB-231 cells compared to cisplatin. To better simulate the human body environment, a 3D spheroid invasion assay was used. This method showed that 1 effectively inhibits tumor spheroids from infiltrating the surrounding extracellular matrix. This study underscores the potential of (arene)ruthenium(II) complexes with naphthopyran ligands as potent antimetastatic agents for chemotherapy.
Clinical assessment ranging from -2=very bad to +2=very good for all patients. Also, profilometry, corneometer and skin elasticity tests in periocular regions and left forearm; skin biopsy on left forearm before/after treatment in B and in 10 randomly selected patients from A. Microscopic evaluation of corneal layer and epidermal thickness, dermal elastosis, new collagen and p53 epidermal expression performed by quantitative digital image analysis. Blind evaluations (group/time) conducted by two independent observers.

Clinical evaluation results showed no alterations (0) or slight improvement (+1) for all patients; profilometry, corneometer and skin elasticity measurements presented a significant difference in pre and post treatment values (p=0,001 to 0,028) with no differences between A/B. Regarding histological findings and p53 expression no previous differences between groups before the treatment were observed (p\>0,1).Quantitative microscopic digital analysis demonstrated no differences between groups at the end of the study for the majority of variables. However, slight but significant difference between A/B subjects was found for p53 with major expression reduction for those treated with oral isotretinoin \[0,66±0,31 vs 0,94±0,34 respectively (p=0,04)\]. The main side effects were cheilitis in 15 patients (75%) and xerophthalmia in 5 (25%). No significant alterations occurred in biochemical tests.
A method of acylating 10-deacetylbaccatin III at the C-10 position to produce baccatin III.   10-deacetylbaccatin III is dissolved in an acceptable ether solvent, such as tetrahydrofuran. A lithium salt, preferably lithium chloride, is added. A trialkylamine base or pyridine is next added, followed by the addition of an acylating agent, such as acetyl chloride. The resulting solution may be quenched, for example with ammonium chloride, to eliminate excess of the acylating agent. The result is baccatin III in solution. This solution may then be diluted with ethyl acetate to form an organic phase and an aqueous phase, with the organic phase being washed and thereafter reduced. Recrystallization and column chromatography may be employed to purify the baccatin III.
PURPOSE:To obtain the titled substrate having large substrate surface area, useful as a substrate for cell culture, and effective to facilitate the mass culture, by dispersing a neutral aqueous solution of collagen in a nonpolar organic solvent to form an emulsion, and solidifying the droplets by increasing the temperature of the emulsion. CONSTITUTION:A neutral solution of collagen is dispersed in the form of a number of droplets in a nonpolar organic solvent (e.g. toluene, CCl4, ether, etc.) at 0-25 deg.C to obtain an emulsion, which is heated at 30-40 deg.C to solidify said droplets. A substrate containing regenerated collagen fibrils can be prepared by this process. The substrate forms a bead composed of an irregularly entangled regenerated collagen fibrils having a diamter of 10-1,000mum and the aqueous solution existing between said fibrils, and contains 20-0.01wt% regenerated collagen fibril. The substrate has large substrate surface area, is effective to facilitate the mass culture of cells, and is useful also as a carrier for the determination of the adhesivity of thrombocyte.
<P>PROBLEM TO BE SOLVED: To obtain a xanthone derivative that has a weak adverse effect and an excellent inhibitory action on inflammatory cytokine production, to provide a method for producing the same and a food preparation, a cosmetic and an anti-inflammatory agent comprising the same.  <P>SOLUTION: The xanthone derivative that has an inhibitory action on inflammatory cytokine production is a derivative obtained by combining xanthone with gluconic acid and a carboxylic acid. The xanthone derivative is acidic, permeates the skin, exhibits an excellent anti-inflammatory action and has high safety. The method for producing the xanthine derivative comprises a process of adding ground soybean and Bacillus natto to ground mangosteen, fermenting the mixture to give a fermented substance and extracting the fermented substance with an acidic aqueous solution. The food preparation and the cosmetic each comprises the xanthone derivative having an inhibitory action on inflammatory cytokine production and a fruit juice essence. The anti-inflammatory agent comprises the xanthone derivative.  <P>COPYRIGHT: (C)2009,JPO&INPIT
HL2 supported care made all of these resources available through interaction with the HL2 device. Participants had access to all resources through the Mixed reality device (HoloLens2). Access to senior support through using the HL2 device.
In this arm, participants will receive spironolactone 100mg/day for the entirety of the study. To maximize the generalizability of the study, participants will be allowed to continue their current topical regimen as long as no changes were made in the 4 weeks prior to randomization. No additions to their topical regimen may be made during the study period.
Patients must have disseminated recurrent medulloblastoma (MB) or ATRT (defined as multifocal disease, positive spine MRI including leptomeningeal disease and/or positive cytology within 21 days prior to study registration) and have adequate CSF flow based on spine MRI with no evidence of bulky disease or if bulky disease is present based on a CSF flow study per institutional guidelines. Patients must have undergone what is considered the standard of care as upfront therapy including either surgery followed by high dose chemotherapy with stem cell rescue or multi-modality therapy of surgery, radiation and chemotherapy. Patients will receive the modified measles virus, MV-NIS, via lumbar puncture (modified measles virus lumbar puncture).
The invention relates to a Chinese patent medicine, and specifically relates to traditional Chinese medicine granules used for treating acute hepatitis. Acute hepatitis or chronic hepatitis active phase show significantly increased alanine aminotransferase. The Ganyanling granules provided by the invention has the functions of liver soothing, heat clearing, liver toxicity relieving, and water retention alleviating. During acute hepatitis or chronic hepatitis active phase, pathogenic evil always dominates, and fierce struggle occurs between the good and the evil. Therefore, pathogenic evil dispelling should be the dominant approach, and detoxification is the key to treatment. However, spleen and stomach damage should be avoided. The invention adopts a technical scheme that: the following medicine materials are adopted: 18% of Chinese thorowax root, 18% of Baikal skullcap root, 18% of artemisiae cagranulearies, 18% of glabrous greenbrier rhizome, 18% of Chinese brake herb, and 10% of paris polyphylla smith; the six Chinese herbal medicines are subjected to ultrafine crushing and uniform mixing; and the material is prepared into granules. For acute hepatitis or chronic hepatitis patients in an active phase in which alanine aminotransferas significantly increases, 8-10g of the Ganyanling granules are taken each time after meal, and three times a day. The granules are infused by using water before being taken. After alanine aminotransferase turns normal, 3-5g of the Ganyanling granules are taken each time after meal, and three times a day.
Non-Naive subjects received one dose and Naive subjects received two doses, administered 4 weeks apart, of control vaccine. Subjects aged 3 to \<4 years and subjects aged 4 to 8 years received different control TIV.
Diabetes is rapidly spreading, affecting a significant number of adults, with a staggering total of 537 million diabetic individuals. This condition gives rise to various complications that can lead to diabetic retinopathy, foot ulcers, cardiac problems, and kidney damage. However, many of these complications can be mitigated by providing patients with accurate information concerning their diet, stress management, and weight control.

The recent advancements in Generative Artificial Intelligence-based chatbots have demonstrated their efficacy as intelligent assistants across various aspects of human life. In this study, we aim to assess the effectiveness of these Language Models in assisting patients. Our research plan entails the interaction between patients and chatbots like ChatGPT, both with and without human support, followed by evaluations of these interactions by specialists. Additionally, we will gather feedback from patients regarding their experiences and perceptions of the chatbot interactions.
The invention relates to polymerizable dental substances which contain; (a) 10 to 98.999 wt. % of at least one bi- or higher functional ethylenically unsaturated monomer; (b) 0 to 88.999 wt. % of at least one monofunctional ethylenically unsaturated monomer; (c) 0 to 5 wt. % of an accelerator; (d) 0.001 to 5 wt. % of a redox initiator system that can initiate the radical polymerization; (e) 0 to 88.999 wt. % of fillers, thixotropy auxiliary agents, retarders and other auxiliary aids, and; (f) 1 to 30 wt. % of a common plasticizers. The inventive polymerizable dental substances are characterized in that the redox initiator system (i) comprises a barbituric acid derivative and/or a malonyl sulfamide and (ii) an organic peroxide, selected from the group of the mono- or polyfunctional carboxylic peroxyesters. The dental substances are also characterized in that constituents (a) to (f) are provided in two spatially separated pastes. The dental substances are suited as filling materials, material for building up stumps, fixing cement, temporary crown and bridge material, and as dental material or is suited for producing inlays, onlays, enameling shells, and materials for models.
BACKGROUND: To investigate the effect of Gypenoside XLIX (Gyp-XLIX) on acute splenic injury (ASI) induced by cecal ligation and puncture (CLP) in septic mice, a study was conducted.
METHODS: Sixty healthy mice were randomly divided into six groups: the NC group, the Sham group, the Sham + Gyp-XLIX group, the CLP group, the CLP + Gyp-XLIX group, and the CLP + Dexamethasone (DEX) group. The NC group did not undergo any operation, while the rest of the groups underwent CLP to establish the sepsis model. The Sham group only underwent open-abdominal suture surgery without cecum puncture. After the operation, the groups were immediately administered the drug for a total of 5 days. Various methods such as hematoxylin and eosin (HE) staining, biochemical kits, qRT-PCR, and reactive oxygen species (ROS) were used for analysis.
RESULTS: The results demonstrated that Gyp-XLIX effectively mitigated the splenic histopathological damage, while reducing the malondialdehyde (MDA) lipid peroxidation index and enhancing the antioxidant activities of catalase (CAT), glutathione (GSH) and total antioxidant capacity (T-AOC). The utilization of Dihydroethidium (DHE) fluorescent probe revealed that Gyp-XLIX inhibited the acute splenic accumulation of ROS induced by CLP in septic mice. Further investigations revealed that Gyp-XLIX exhibited a down-regulatory effect on the protein levels of inflammatory mediators iNOS and COX-2, consequently leading to the suppression of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β. Additionally, it up-regulated the expression of anti-inflammatory factor IL-10.
CONCLUSION: In conclusion, Gyp-XLIX was significantly effective in attenuating CLP-induced acute splenic inflammation and oxidative stress in septic mice.
Patients receive pembrolizumab IV over 30 minutes on day 1, ipilimumab IV over 60 minutes on day 1 for courses 1-4, and aspirin PO BID (orally, twice a day) on days 1-21. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.